CureVac is ready to compete in the big leagues with its vaccines, according to a UBS analyst who says the soaring stock has more room to rise.
UBS analyst Eliana Merle upgraded the shares (ticker: CVAC) to Buy from Neutral and raised her 12-month target for the stocks price to $18 from $8 on Thursday. Merle listed recent clinical trial data and the biopharmaceutical company’s ability to gain market share as reasons for the upgrade.
Source: finance.yahoo.com
Related posts:
Jack Ma Loses $683 Million on Alibaba Days Before Big Stake Sale
Lululemon, Intel, Carnival, Micron, Walgreens, and More Stocks to Watch This Week
BP and Shell Are a Buy. Why They’re Cheaper Than U.S. Oil Giants.
Mt. Gox Begins Repayments in Bitcoin and Bitcoin Cash
Teladoc loses $3 billion in three months, stock plummets 24%